ClinicalTrials.Veeva
Menu

Find clinical trials for Leukemia in Dallas, TX

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Myeloid Leukemia
Acute Myeloid Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Lymphoma
Myelodysplastic Syndromes

Leukemia trials near Dallas, TX, USA:

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase 1. In Phase 2, assessment of ziftomenib wil...

Enrolling
Acute Leukemia of Ambiguous Lineage
Mixed Phenotype Acute Leukemia
Drug: Ziftomenib

Phase 1, Phase 2

Kura Oncology

Dallas, Texas, United States and 51 other locations

Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

in treating pediatric and young adult patients with acute myeloid leukemia (AML) or acute leukemia of ambiguous lineage (ALAL) that...

Enrolling
Refractory Acute Leukemia of Ambiguous Lineage
Acute Myeloid Leukemia, in Relapse
Drug: Methotrexate
Drug: Venetoclax

Phase 1

St. Jude Children's Research Hospital
St. Jude Children's Research Hospital

Dallas, Texas, United States and 10 other locations

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

The overarching objective of this study is to use novel precision medicine strategies based on inherited and acquired leukemia-specific geno...

Active, not recruiting
Acute Lymphoblastic Leukemia
Acute Lymphoblastic Lymphoma
Drug: Asparaginase Erwinia chrysanthemi (recombinant)-rywn
Drug: Thioguanine

Phase 2, Phase 3

St. Jude Children's Research Hospital
St. Jude Children's Research Hospital

Fort Worth, Texas, United States and 7 other locations

Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients (ASSURE)

(bid) in approximately 540 participants with chronic lymphocytic leukemia (CLL). Participants will be enrolled into 3 following cohorts: tre...

Active, not recruiting
Chronic Lymphocytic Leukemia
Drug: Acalabrutinib

Phase 3

AstraZeneca
AstraZeneca

Dallas, Texas, United States and 108 other locations

Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (SIERRA)

allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid Leukemia...

Active, not recruiting
Acute Myelogenous Leukemia
Leukemia, Acute Myeloid
Drug: Iomab-B
Drug: Conventional Care

Phase 3

Actinium Pharmaceuticals
Actinium Pharmaceuticals

Dallas, Texas, United States and 23 other locations

A Phase 1, Study of BMF-500 in Adults With Acute Leukemia

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia....

Enrolling
Acute Mixed-Phenotype Leukemia
Acute Lymphoblastic Leukemia
Drug: BMF-500

Phase 1

Biomea Fusion

Dallas, Texas, United States and 22 other locations

Recently updated

ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

This study is evaluating the safety and efficacy of a new BTK inhibitor, acalabrutinib, for the treatment of chronic lymphocytic leukemia (C...

Active, not recruiting
Chronic Lymphocytic Leukemia
Prolymphocytic Leukemia
Drug: Acalabrutinib

Phase 1, Phase 2

Acerta Pharma
Acerta Pharma

Fort Worth, Texas, United States and 11 other locations

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (rux...

Active, not recruiting
Leukemia
Drug: Methotrexate
Drug: Thioguanine

Phase 2

Incyte
Incyte

Dallas, Texas, United States and 110 other locations

A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) (ASC4START)

of asciminib versus nilotinib for the treatment of newly diagnosed, previously untreated patients with Positive Chronic Myelogenous Leukemia...

Active, not recruiting
Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
Drug: Nilotinib
Drug: Asciminib

Phase 3

Novartis
Novartis

Bedford, Texas, United States and 120 other locations

A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

of the combinations of AG-120 with azacitidine and AG-221 with azacitidine versus with azacitidine alone in participants with acute myeloid leukemia...

Active, not recruiting
Leukemia, Myeloid, Acute
Drug: Azacitidine
Drug: AG-120

Phase 1, Phase 2

Celgene
Celgene

Dallas, Texas, United States and 48 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems